Pharma Stock which is India’s leading animal health company, engaged in providing a wide-ranging portfolio including Finished Dose Formulations, APIs, and many more jumped 11 percent in the day’s trade upon receiving prequalification (PQ) approval for its API from the World Health Organization.
Price Action
With a market capitalization of Rs. 4,070 Crores, the shares of Sequent Scientific Limited were trading at Rs. 163 per equity share, up 4 percent from its previous day’s close price of Rs. 157.35. It has delivered a return of 84 percent in a year.
What Happened
Sequent Scientific Limited has received prequalification (PQ) approval from the World Health Organization (WHO) for Albendazole, Active Pharmaceutical Ingredient (API). This was developed in partnership with Mepro Pharmaceuticals Private Limited, who have successfully developed and commercialized the Albendazole Chewable formulation from its WHO prequalification-approved plant, using its API.
Albendazole is a vital medication used to treat a range of parasitic infections, including tapeworm, roundworm, and hookworm infestations, affecting millions globally, particularly in low and middle-income countries.
The WHO prequalification recognizes Sequent Scientific Limited’s commitment to stringent international standards in the production of Albendazole API, ensuring efficacy, safety, and quality
Management Message
Rajaram Narayanan, MD & CEO of Sequent Scientific Limited said “The WHO prequalification approval validates our manufacturing capabilities and reinforces our dedication to providing high-quality, affordable medicines to those in need worldwide. By leveraging our extensive distribution network and strategic partnerships, the company is poised to make a meaningful impact on health outcomes on a global scale,”
About the Company
Sequent Scientific Limited is India’s leading animal health company, with a presence in 5+ continents across 100 countries. It provides a wide-ranging portfolio of animal health products, including Finished Dose Formulations, APIs, as well as analytical services to the pharmaceutical and life sciences industries.
Financials and Ratios
Its Revenue from operations grew by 17.11 percent from Rs. 333.21 Crores in Q1FY24 to Rs. 390.21 Crores in Q1FY25, accompanied by a loss of Rs. 34.68 Crores to Rs. 9.06 Crores.
In terms of Return ratios, it has reported a return on equity (ROE) of -2.46 percent, and a return on capital employed (ROCE) of 0.90 percent. It has reported a debt-to-equity ratio of 0.74.
Written by: Bharath K.S
Disclaimer
The views and investment tips expressed by investment experts/broking houses/rating agencies on tradebrains.in are their own, and not that of the website or its management. Investing in equities poses a risk of financial losses. Investors must therefore exercise due caution while investing or trading in stocks. Dailyraven Technologies or the author are not liable for any losses caused as a result of the decision based on this article. Please consult your investment advisor before investing.
